Olorinab

Olorinab
Clinical data
Routes of; administration	Oral
Identifiers
	IUPAC name (4aS,5aS)-N-((2S)-1-hydroxy-3,3-dimethylbutan-2-yl)-1-(4-oxidopyrazin-2-yl)-4,4a,5,5a-tetrahydro-1H-cyclopropa(4,5)cyclopenta[1,2-c]pyrazole-3-carboxamide;
CAS Number	1268881-20-4;
PubChem CID	60164925;
Chemical and physical data
Formula	C18H24N5O3
Molar mass	358.414 g/mol
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C)[C@@H](CO)NC(=O)C1=NN(C2=C1C[C@H]3[C@@H]2C3)C4=NC=C[N+](=C4)[O-];
	InChI InChI=1S/C18H23N5O3/c1-18(2,3)13(9-24)20-17(25)15-12-7-10-6-11(10)16(12)23(21-15)14-8-22(26)5-4-19-14/h4-5,8,10-11,13,24H,6-7,9H2,1-3H3,(H,20,25)/t10-,11-,13+/m0/s1; Key:ACSQLTBPYZSGBA-GMXVVIOVSA-N;

Olorinab (APD371) is a drug developed by Arena Pharmaceuticals for the treatment of pain associated with Crohn's disease. It acts as a potent and selective cannabinoid CB₂ receptor agonist and is claimed to be orally active and peripherally selective, and has progressed to Phase II clinical trials.^[1]^[2]

References

↑ Han S, Thoresen L, Jung JK, Zhu X, Thatte J, Solomon M, et al. (December 2017). "Discovery of APD371: Identification of a Highly Potent and Selective CB2 Agonist for the Treatment of Chronic Pain". ACS Medicinal Chemistry Letters. 8 (12): 1309–1313. doi:10.1021/acsmedchemlett.7b00396. PMID 29259753.
↑ "Olorinab (APD371)". Arena Pharmaceuticals, Inc.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

Clinical data

Routes of administration	Oral
Identifiers
IUPAC name (4aS,5aS)-N-((2S)-1-hydroxy-3,3-dimethylbutan-2-yl)-1-(4-oxidopyrazin-2-yl)-4,4a,5,5a-tetrahydro-1H-cyclopropa(4,5)cyclopenta[1,2-c]pyrazole-3-carboxamide
CAS Number	1268881-20-4
PubChem CID	60164925
Chemical and physical data
Formula	C₁₈H₂₄N₅O₃
Molar mass	358.414 g/mol
3D model (JSmol)	Interactive image
SMILES CC(C)(C)[C@@H](CO)NC(=O)C1=NN(C2=C1C[C@H]3[C@@H]2C3)C4=NC=C[N+](=C4)[O-]
InChI InChI=1S/C18H23N5O3/c1-18(2,3)13(9-24)20-17(25)15-12-7-10-6-11(10)16(12)23(21-15)14-8-22(26)5-4-19-14/h4-5,8,10-11,13,24H,6-7,9H2,1-3H3,(H,20,25)/t10-,11-,13+/m0/s1 Key:ACSQLTBPYZSGBA-GMXVVIOVSA-N